New payment models, dedicated investment, and better health technology assessment are among a raft of changes needed to bring regenerative medicines to patients in Europe, according to a ne
New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.
AstraZeneca is appealing against NICE’s decision not to recommend funding for its lung cancer drug Tagrisso (osimertinib) in untreated patients with epidermal growth factor receptor (EGFR)
Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer immunotherapy Libtayo, after NICE recommended funding for a form of skin cancer immed
Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
NHS England is to prioritise cancer drugs that target tumours according to their genetic makeup rather than where they originate in the body, the organisation’s chief executive has said.